


## Supplementary Information



**Figure S1.** Kaplan Meier plot for overall survival in patients with DLBCL ( $n = 32$ ) stratified by miR-199a expression level in an analysis of a freely available data set recently published by Caramuta *et al.* [22].

**Table S1.** Drugs, Doses, and Source used in the study.

Drug	Doses (nM)	Source
Rituximab	0.1, 0.25, 0.5, 1	Roche Austria GMBH, Vienna, Austria
Cyclophosphamide	1, 10, 25, 50	Baxter Oncology GMBH, Halle, Germany
Doxorubicin	0.01, 0.03, 0.05	Pfizer Service Company BVBA, Zaventem, Belgium
Vincristin	0.0005, 0.001, 0.0025, 0.005	Pfizer Italia S.R.L. Nerviano, Italy